Med18 Inhibitors
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylases (HDACs), which could lead to hyperacetylation of histones, potentially disrupting the transcriptional regulation and recruitment capabilities of Med18 within the mediator complex, thereby inhibiting its function. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $311.00 | ||
Flavopiridol inhibits cyclin-dependent kinases (CDKs). Since CDKs are involved in the phosphorylation of mediator complex subunits, this could inhibit Med18 function by preventing phosphorylation events that are necessary for its activity in transcription. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide has been shown to inhibit RNA Polymerase II (Pol II) transcriptional activity. Since Med18 is part of the mediator complex that facilitates Pol II function, triptolide would inhibit Med18 by preventing its role in Pol II driven transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB) inhibits CDK9 and CDK12, which are involved in the C-terminal domain (CTD) phosphorylation of Pol II. Inhibition here would prevent Med18 from effectively participating in Pol II-mediated transcription elongation. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Silvestrol is an eIF4A translational inhibition agent. By inhibiting translation initiation, it can reduce the overall availability of Med18 by preventing its synthesis, leading to a functional inhibition of the protein's activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $92.00 $182.00 | 71 | |
H-89 is a protein kinase A (PKA) inhibitor. Given PKA's role in various signaling pathways that could phosphorylate components of the mediator complex, inhibiting PKA can impair Med18's function by reducing necessary phosphorylation events. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
C646 is a competitive inhibitor of the acetyltransferase p300, which could result in decreased acetylation of Med18 or its associated factors within the mediator complex, leading to impaired function of Med18 in transcriptional regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, potentially increasing the level of ubiquitinated proteins; this could indirectly lead to the sequestration of ubiquitin ligases or cofactors required for Med18 function, inhibiting its activity. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor of CDKs 2, 7, and 9. By inhibiting these CDKs, it can prevent phosphorylation of the mediator complex subunits, including Med18, thereby inhibiting Med18's role in transcription. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, potentially causing a cellular stress response that could include the inhibition of Med18 by diverting cellular resources away from transcriptional activation processes. | ||||||